These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38656587)

  • 1. Antibody-independent surface plasmon resonance assays for influenza vaccine quality control.
    Serafin B; Kamen A; de Crescenzo G; Henry O
    Appl Microbiol Biotechnol; 2024 Apr; 108(1):307. PubMed ID: 38656587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring.
    Durous L; Julien T; Padey B; Traversier A; Rosa-Calatrava M; Blum LJ; Marquette CA; Petiot E
    Vaccine; 2019 Mar; 37(12):1614-1621. PubMed ID: 30773402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.
    Khurana S; King LR; Manischewitz J; Coyle EM; Golding H
    Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies.
    Narayan K; Paduraru C; Blake T; Arunachalam AB
    Front Immunol; 2023; 14():1128683. PubMed ID: 37457687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical review of current and emerging quantification methods for the development of influenza vaccine candidates.
    Manceur AP; Kamen AA
    Vaccine; 2015 Nov; 33(44):5913-9. PubMed ID: 26271833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.
    Gravel C; Li C; Wang J; Hashem AM; Jaentschke B; Van Domselaar G; He R; Li X
    J Vis Exp; 2011 Apr; (50):. PubMed ID: 21490585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.
    Khurana S; Larkin C; Verma S; Joshi MB; Fontana J; Steven AC; King LR; Manischewitz J; McCormick W; Gupta RK; Golding H
    Vaccine; 2011 Aug; 29(34):5657-65. PubMed ID: 21704111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.
    Vodeiko GM; Weir JP
    Influenza Other Respir Viruses; 2012 May; 6(3):176-87. PubMed ID: 21902817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay.
    Lorbetskie B; Cunningham AM; Lemieux M; Durno L; Farnsworth A; Wang J; Li C; Li X; Gilbert M; Sauvé S; Girard M
    Anal Chem; 2019 Jul; 91(14):8908-8917. PubMed ID: 31251585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance.
    Bruce-Staskal PJ; Woods RM; Borisov OV; Massare MJ; Hahn TJ
    Vaccine; 2020 Oct; 38(43):6757-6765. PubMed ID: 32928588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines.
    Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S
    Front Immunol; 2023; 14():1147028. PubMed ID: 37033922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
    Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
    Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.
    Moody MA; Zhang R; Walter EB; Woods CW; Ginsburg GS; McClain MT; Denny TN; Chen X; Munshaw S; Marshall DJ; Whitesides JF; Drinker MS; Amos JD; Gurley TC; Eudailey JA; Foulger A; DeRosa KR; Parks R; Meyerhoff RR; Yu JS; Kozink DM; Barefoot BE; Ramsburg EA; Khurana S; Golding H; Vandergrift NA; Alam SM; Tomaras GD; Kepler TB; Kelsoe G; Liao HX; Haynes BF
    PLoS One; 2011; 6(10):e25797. PubMed ID: 22039424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.
    Velkov T; Ong C; Baker MA; Kim H; Li J; Nation RL; Huang JX; Cooper MA; Rockman S
    Mol Immunol; 2013 Dec; 56(4):705-19. PubMed ID: 23933511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.
    Chae W; Kim P; Hwang BJ; Seong BL
    Vaccine; 2019 Mar; 37(11):1457-1466. PubMed ID: 30765169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance.
    Mandenius CF; Wang R; Aldén A; Bergström G; Thébault S; Lutsch C; Ohlson S
    Anal Chim Acta; 2008 Aug; 623(1):66-75. PubMed ID: 18611459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.